Current Report Filing (8-k)
January 16 2020 - 5:01PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
January 15, 2020
Date of Report
Q
BioMed Inc.
(Exact name of registrant as specified in
its charter)
Nevada
|
333-193328
|
46-4013793
|
(State or other jurisdiction of incorporation)
|
(Commission File Number)
|
(IRS Employer Identification No.)
|
c/o Ortoli Rosenstadt LLP
|
|
10022
|
(Address of principal executive offices)
|
|
(Zip Code)
|
(212) 588-0022
Registrant’s telephone number, including
area code
Check the appropriate box below if the Form 8-K is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class:
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered:
|
None
|
|
None
|
|
None
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ¨
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
|
Item 1.01
|
Entry into a Material Definitive Agreement
|
On January 15,
2020, we issued a debenture for $1,000,000 pursuant to a securities purchase agreement with an accredited investor dated December
6, 2019. The debenture has a maturity date of June 6, 2021, provided that in case of an event of default, the debenture may become
at the holder’s election immediately due and payable. The debenture bears interest at the rate of 5.5% per annum, and on
issuance, we paid to the holder a commitment fee equal to 2.5% of the amount of the debenture.
The holder may
convert the debenture in its sole discretion at any time on or prior to maturity at the lower of $3.00 or 93% of the average of
the four lowest daily VWAPs during the 10 consecutive trading days immediately preceding the conversion date, provided that the
conversion price may never be less than $2.00. We may not convert any portion of the debenture if such conversion would result
in the holder beneficially owning more than 4.99% of our then issued and common stock, provided that such limitation may be waived
by the holder with 65 days’ notice.
Any time after
the six-month anniversary of the issuance of the debenture that the daily VWAP is less than $2.00 for a period of twenty consecutive
trading days (the “Triggering Date”) and only for so long as such conditions exist after a Triggering Date, we shall
make monthly payments beginning on the last calendar day of the month when the Triggering Date occurred. Each monthly payment shall
be in an amount equal to the sum of (i) the principal amount outstanding as of the Triggering Date divided by the number of such
monthly payments until maturity, (ii) a redemption premium of 20% in respect of such principal amount and (iii) accrued and unpaid
interest hereunder as of each payment date. We may, no more than twice, obtain a thirty-day deferral of a monthly payment due as
a result of a Triggering Date through the payment of a deferral fee in the amount equal to 10% of the total amount of such monthly
payment. Each deferral payment may be paid by the issuance of such number of shares as is equal to the applicable deferral payment
divided by a price per share equal to 93% of the average of the four lowest daily VWAPs during the 10 consecutive Trading Days
immediately preceding the due date in respect of such monthly payment being deferred, provided that such shares issued will be
immediately freely tradable shares in the hands of the holder.
|
Item 3.02
|
Unregistered Sale of Equity Securities
|
The information
set forth in Item 1.01 hereof is incorporated by reference into this Item 3.02.
The securities
mentioned above were issued in reliance on exemptions from registration under Section 4(2) of the Securities Act of 1933, as amended
(the “Act”), and Rule 506 of Regulation D promulgated under the Act. These transactions qualified
for exemption from registration because among other things, the transaction did not involve a public offering, the investor was
an accredited investor and/or qualified institutional buyer, the investor had access to information about our company and its investment,
the investor took the securities for investment and not resale, and we took appropriate measures to restrict the transfer of the
securities.
|
Item 9.01
|
Financial Statements and Exhibits.
|
Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act
of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Q BioMed Inc.
|
|
|
|
|
|
Date: January 15, 2020
|
By:
|
/s/ Denis Corin
|
|
|
Name:
|
Denis Corin
|
|
|
Title:
|
President
|
|
Q BioMed (CE) (USOTC:QBIO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Q BioMed (CE) (USOTC:QBIO)
Historical Stock Chart
From Sep 2023 to Sep 2024